Q Biomed Advisor And Mannin Research CSO Dr Susan Quaggin Elequently Discusses Glaucoma And Man-01 With Eye On Vision Radio
Q BioMed Inc. (OTCQB: QBIO), partner Mannin Research Inc. CSO Dr. Susan Quaggin discusses glaucoma, treatment options, and her novel findings on the relationship between Tie2/TEK signaling, Schelmm's Canal and glaucoma with Eye on Vision. In the interview Dr. Quaggin explains intraocular pressure (IOP), one of the major causes of glaucoma and her research into understanding Tie2/TEK signalling and its relationship with Schlemm's Canal function and regulation of intra-ocular pressure.
Mannin's researchers have received the first of several drug candidates for testing. Once finalized, the lead candidates will be formulated for clinical testing in a topical application in the form of an easy to administer eye drop. This is a key differentiator for Mannin and aims to solve the compliance problems and invasive procedures currently available to patients suffering from glaucoma.
In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics including the technology discussed here.
To listen to the interview, please visit the Eye On Vision podcast here, http://eyeonvision.blogspot.ca/2016/06/dr-susan-quaggin-and-eyewear-gallerys.html
For more on Mannin Inc. please visit http://www.mannin.ca
Please visit our website http://www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.
About Q BioMed Inc.
Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
George N. Nikopoulos
CEO
Mannin Research Inc.
+1-416-775-9767